Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Authors:
- 1 February 2019
- journal article
- research article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 54, 114-120
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (HHSN261200800001E)
- Frederick National Laboratory for Cancer Research (HHSN261200800001E)
- Government of South Australia (HHSN261200800001E)
- U.S. Department of Health and Human Services (HHSN261200800001E)
- National Institutes of Health (HHSN261200800001E)
This publication has 75 references indexed in Scilit:
- Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras-Driven Hematopoietic TransformationCancer Discovery, 2013
- Application of Reductive 13C-Methylation of Lysines to Enhance the Sensitivity of Conventional NMR MethodsMolecules, 2013
- Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α ( PIK3CA )Proceedings of the National Academy of Sciences, 2012
- Both the C-Terminal Polylysine Region and the Farnesylation of K-RasB Are Important for Its Specific Interaction with CalmodulinPLOS ONE, 2011
- A frequent kinase domain mutation that changes the interaction between PI3Kα and the membraneProceedings of the National Academy of Sciences, 2009
- The Hypervariable Region of K-Ras4B Is Responsible for Its Specific Interactions with CalmodulinBiochemistry, 2009
- The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulationCurrent Opinion in Genetics & Development, 2009
- Phospholipase C isozymes as effectors of Ras superfamily GTPasesJournal of Lipid Research, 2009
- Rassf Family of Tumor Suppressor PolypeptidesJournal of Biological Chemistry, 2009
- Structural insight into dimeric interaction of the SARAH domains from Mst1 and RASSF family proteins in the apoptosis pathwayProceedings of the National Academy of Sciences, 2007